Page 5 - Stock Analysis

V-Mart's turnaround gathers pace as margins rise, stores scale up: Analysts

After three years of store rationalisation and pricing corrections, Unlimited's newer stores are now performing in line with core V-Mart outlets.

Ajanta Pharma shares up 3% as Biocon tie-up fuels long-term growth optimism

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide opportunity, and growth outlook

HDFC Sec upgrades Max Healthcare on strong expansion-led growth outlook

On the bourses, however, Max Healthcare share price was trading 1.75 per cent lower at ₹1,044.75 per share around 11:30 AM. By comparison, BSE Sensex was trading 0.07 per cent lower at 84,637.50.

Motilal Oswal stays bullish on Indigo Paints, bets on demand recovery

The brokerage has reiterated its 'Buy' rating on the stock, with a revised target price of ₹1,450, valuing the company at 35x Dec'27E earnings.

Skipper newly rated 'Buy' at Systematix; 17% upside potential seen

Skipper is among the top 10 transmission tower manufacturers globally and has built a strong cost advantage through high backward integration, sourcing nearly 90 per cent of its raw materials in-house

What does Coforge's Encora acquisition mean for investors? Analysts weigh

Brokerages see the acquisition as aligned with Coforge's stated ambition to shift more deeply into higher-value, AI-driven engineering services

Lenskart: Emkay Global sees 6x revenue growth potential, initiates 'Buy'

Lenskart stock gets 'Buy' rating from Emkay Global with ₹525 target as brokerage highlights market leadership, tech edge and strong growth outloo

Axis Bank's growth improving; NIMs to bottom in Q4FY26/Q1: Motilal Oswal

The brokerage has reiterated its 'Neutral' rating on the stock with a target price of ₹1,300 after its interaction with the top management team of Axis Bank

Ashok Leyland set to ride CV upcycle; Choice hikes target, retains 'Buy'

The brokerage believes Ashok Leyland is poised to be a major beneficiary of India's ongoing commercial vehicle (CV) upcycle, helped by firming domestic demand, rising exports

Is Northern Arc your next growth stock? Ambit says 'Buy', 30% upside eyed

Northern Arc's long experience in finance placement and fund management should support fee income, helping absorb structurally higher credit costs, analysts at Ambit said

Mirae Asset Sharekhan sees upside for Lodha on launches, Palava push

On the bourses, meanwhile, Lodha Developers share price was trading 0.09 per cent lower at ₹1,078.40 per share around 10:50 AM. By comparison, BSE Sensex was trading 0.21 per cent lower at 85,226.75.

Motilal Oswal sees strong growth visibility for Brigade Ent; retains 'Buy'

Motilal Oswal believes Brigade Enterprises is now entering a new phase of geographic and asset-class expansion, led by fresh residential, commercial and hospitality bets beyond its Bengaluru core

Ajanta Pharma to generate healthy margins from Biocon deal: PL Capital

According to PL Capital, Ajanta Pharma's strong franchise will aid in garnering a higher market share for semaglutide

Margins, valuation hurdles for Eicher Motors despite strong volume gains

Royal Enfield's growth was primarily driven by the strong demand for Bullet 350 which saw a volume gain of 59 per cent Y-o-Y on a YTD basis

PL Capital hikes Adani Ports target on NQXT acquisition; retains 'Buy'

PL Capital maintained 'Buy' as it builds in stronger volumes and margins following the acquisition of North Queensland Export Terminal (NQXT)

Antique reaffirms 'Buy' on Jindal Steel; expects expansions to fuel profit

The brokerage believes that cost efficiencies from increased captive coal, a slurry pipeline, and higher captive power generation will support margins

Hero MotoCorp 2W demand to stay strong; rural, exports boost: Motilal Oswal

The company expects the momentum to continue in the second half of the fiscal year (H2FY26), with overall industry volume growth projected at 8-10 per cent.

Why did Systematix initiate coverage on JTEKT India? 33% upside seen

Systematix has set a target price of ₹192 for JTEKT India, valuing the stock at EV/Ebitda of 17.5 times on December 2027E, in line with its past five-year average multiple

Emkay raises Bank of Baroda target to ₹350 on strong FY26 growth outlook

Analysts at Emkay Global Financial Services have raised Bank of Baroda's share price target to ₹350 with a 'Buy' rating, citing 11-13% credit growth outlook, stable margins, and strong asset quality

Anand Rathi starts coverage on Jubilant Ingrevia with 'Buy'; check target

Anand Rathi expects Jubilant's capex cycle to drive a sharp earnings upturn over FY26-28, with consolidated Ebitda seen growing at around a 22 per cent CAGR